Atrial fibrillation (AF) is one of the most common heart rhythm disorders, characterized by chaotic and irregular contraction of the atria. This condition significantly increases the risk of serious complications, primarily ischemic stroke, which can be caused by blood clots forming in the atria and subsequently breaking off into the bloodstream. This is why anticoagulant therapy is the cornerstone in the treatment of patients with AF, aimed at preventing these dangerous thromboembolic events.
The Evolution of Anticoagulant Therapy in Atrial Fibrillation
The medical landscape in cardiovascular disease management is constantly changing, and atrial fibrillation is no exception. In recent years, new data and approaches to managing this condition have emerged, particularly regarding anticoagulation [1]. These changes are important for both specialists and general practitioners who frequently encounter patients with AF. Modern studies and clinical guidelines aim to optimize the choice of anticoagulants, taking into account the individual characteristics of each patient and the balance between efficacy and safety.
Risks of Anticoagulant Therapy: Focus on Bleeding
Despite the vital role of anticoagulants in preventing thrombosis, their use carries a risk of bleeding. Antithrombotic drugs, which include both anticoagulants and antiplatelet agents, predispose patients to the development of acute and chronic subdural hematomas [2]. Patients taking these drugs have a higher likelihood of developing large hematomas and more severe neurological impairments [2].
Of particular danger are intracranial hemorrhages (ICH), which are the most serious complication of oral anticoagulant therapy [5]. Although the understanding of oral anticoagulant-associated ICH remains limited compared to spontaneous ICH, it is clear that this condition requires special attention [5].
Bleeding Management and Anticoagulant Reversal Strategies
In cases where a patient taking anticoagulants develops severe bleeding, such as a subdural hematoma, standard neurosurgical and neuro-intensive care includes the discontinuation of antithrombotic therapy prior to surgery [2]. Various strategies exist for reversing antithrombotic agents, depending on the type of drug and the clinical situation [2].
However, despite the need for emergency intervention, standardized guidelines for the management of oral anticoagulant-induced ICH are still lacking [5]. Current treatment methods aim to normalize iatrogenic blood clotting disorders, but they are not always based on evidence from randomized controlled trials [5].
An important advancement in the management of bleeding caused by direct oral anticoagulants (DOACs) has been the emergence of specific antidotes. For example, andexanet alfa is a novel antidote for factor Xa (FXa) inhibitors [7]. The ANNEXA-I study showed that the use of andexanet in patients with intracranial hemorrhage associated with FXa inhibitor use reduces the risk of hematoma expansion. However, it is important to note that this also increases the risk of arterial thromboembolic events [7]. This highlights the delicate balance that must be considered when choosing a treatment strategy.
Patients with ICH caused by oral anticoagulant therapy often have a high risk of cardioembolism and myocardial infarction. Consequently, the use of procoagulant treatments to stop bleeding can increase the risk of thrombotic complications, creating a dilemma for physicians [5].
Balancing Thrombosis and Bleeding Risks
Choosing the optimal anticoagulant therapy strategy in atrial fibrillation is always a compromise between minimizing the risk of thromboembolic events and preventing major bleeding. Continuous analysis of clinical trials is necessary to develop optimal strategies that reduce the rate of adverse cardiovascular events while balancing bleeding risks [8].
For patients receiving chronic oral anticoagulant therapy, having effective treatments for acute ICH while minimizing potential thrombotic risks is critically important [5]. An individualized approach, careful assessment of bleeding risk factors (e.g., the HAS-BLED score) and thromboembolism risk factors (e.g., the CHA2DS2-VASc score), as well as regular patient monitoring, are key elements in the successful management of such patients.
Conclusion
Anticoagulant therapy plays a central role in preventing strokes and other thromboembolic complications in patients with atrial fibrillation. Despite significant advancements in this field, including the advent of new drugs and antidotes, risk management, particularly regarding bleeding, remains a complex challenge. The continuous evolution of medical knowledge and the emergence of new data help physicians make more informed decisions, ensuring the best possible outcome for patients. An individualized approach based on a careful risk-benefit analysis is the foundation of effective and safe anticoagulant therapy.
References
- [1] Cardiology: What You Might Have Missed in 2025. https://pubmed.ncbi.nlm.nih.gov/41974015/
- [2] Perioperative Management of Anticoagulant Therapy. https://pubmed.ncbi.nlm.nih.gov/28325463/
- [5] Iatrogenic Causes of Intracranial Hemorrhage: Oral Anticoagulant Therapy. https://pubmed.ncbi.nlm.nih.gov/18289410/
- [7] Association of Biomarkers with Intracranial Hematoma Expansion and Arterial Thromboembolic Events in Patients with Acute Intracranial Hemorrhage: ANNEXA-I Biomarker Subgroup Study. https://pubmed.ncbi.nlm.nih.gov/40289797/
- [8] Canadian Cardiovascular Society/Canadian Association for Interventional Cardiology: Focused Update of the 2023 Guidelines for the Use of Antiplatelet Therapy. https://pubmed.ncbi.nlm.nih.gov/38104631/
Disclaimer: The information provided in this article is for reference purposes only and does not constitute a guide to self-treatment. Before starting any treatment or changing your current therapy, be sure to consult a qualified medical professional.